Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Retrospective study on antihyperlipidemic efficacy and safety of simvastatin, ezetimibe and their combination in korean adults

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Lee, Y. H.
  • Kim, M. J.
  • Choi, C. I.
  • Bae, J. W.
  • Jang, Choon-Gon
  • Lee, S. Y.

publication date

  • August 2011

journal

  • Archives of Pharmacal Research  Journal

abstract

  • Antihyperlipidemic agents such as 3-hydroxymethyglutaryl-coenzyme A reductase inhibitors and cholesterol transporter inhibitors are used in coronary heart disease. However, controversy remains over the pharmacologic effects and safety of these drugs, especially when used in combination therapies. This retrospective study evaluated the therapeutic effect and safety of simvastatin 20 mg and ezetimibe 10 mg combination therapy compared to simvastatin 20 mg or ezetimibe 10 mg monotherapy in Korean patients according to gender, age, baseline low-density lipoprotein cholesterol, and cardiovascular risk factors. We observed significant differences among patient subgroups. Simvastatin and ezetimibe monotherapies and combination therapy reduced low-density lipoprotein cholesterol levels by 27.6%, 10.1%, and 36.8% (p < 0.001) and total cholesterol levels by 17.5%, 9.2%, and 25.3% (p < 0.001), respectively. Both monotherapy and combination therapy groups had similar incidences of all types of adverse events. However, one case of rhabdomyolysis was observed in the combination therapy group. These results suggest that, compared to monotherapy, combination therapy has an additive effect that is not influenced by risk factors. Despite the low incidence of adverse events, caution is required when using these drugs, especially in the context of musculoskeletal side effects.

subject areas

  • Adult
  • Aged
  • Asian Continental Ancestry Group
  • Azetidines
  • Cholesterol
  • Cholesterol, LDL
  • Coronary Disease
  • Drug Combinations
  • Drug Synergism
  • Ezetimibe
  • Ezetimibe, Simvastatin Drug Combination
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypercholesterolemia
  • Korea
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Simvastatin
  • Treatment Outcome
  • Triglycerides
scroll to property group menus

Identity

International Standard Serial Number (ISSN)

  • 0253-6269

Digital Object Identifier (DOI)

  • 10.1007/s12272-011-0813-9

PubMed ID

  • 21910055
scroll to property group menus

Additional Document Info

start page

  • 1331

end page

  • 1337

volume

  • 34

issue

  • 8

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support